PFE - Corbus: Nectin-4 Targeting Proven With U.S. Data On The Way Early 2025
2024-06-03 13:03:00 ET
Summary
- Corbus Pharmaceuticals Holdings, Inc. reported positive results achieved in phase 1 China study, using CRB-701 for patients with mUC and cervical cancer; 44% and 43% ORR achieved for each, respectively.
- The global urothelial carcinoma market is expected to reach $6.82 billion in 2032.
- It is expected that the global cervical cancer treatment market could reach $12.63 billion by 2030.
- Results from the phase 1 U.S. and European study, using CRB-701 for patients with mUC and cervical cancer, expected in Q1 of 2025.
Corbus Pharmaceuticals Holdings, Inc. ( CRBP ) recently reported positive data from its phase 1 study using CRB-701 for the treatment of patients with metastatic urothelial carcinoma [mUC] and cervical cancer. However, this was data that was reported by its partner CSPC in China. It was noted that all patients who were given a dose of >=2.7mgs/kg of this drug were able to achieve some type of response. Not only that, but despite being a nectin-4 targeting antibody-drug conjugate [ADC], it was shown to be safer than Pfizer ( PFE ) Nectin-4 ADC Padcev. This is due to the way it was structured to reduce free roaming MMAE, which led to a reduction of patients having skin rash and peripheral neuropathy....
Corbus: Nectin-4 Targeting Proven With U.S. Data On The Way Early 2025